MSRB2 and Parkinson disease: Although there was no significant difference in Parkin levels compared to age‐matched controls, the Parkinson's disease patients demonstrated a significant reduction in MsrB2 with reduction in LC3II and increased platelet apoptosis (Fig 8A and B).